Skip to content
2000
Volume 26, Issue 3
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Introduction

Drug interactions necessitate careful consideration in clinical practice. It is imperative for clinicians and pharmacists to monitor drug exposure and the co-administration of medications promptly in order to avert adverse outcomes and achieve optimal efficacy.

Objectives

The prevalence of oral lesions varies from 28% to 60% in the short term after renal transplantation. The clinical use of metronidazole in the treatment of anaerobic bacterial infections among solid organ transplant recipients has been complicated by the potentially significant and unpredictable drug-drug interactions.

Methods

We present an unexpected clinically significant drug-drug interaction between tacrolimus and metronidazole in the early period after renal transplantation and describe the potential mechanism and clinical characteristics of this drug-drug interaction through a literature review.

Results

A 34-year-old female experienced a 65% increase in dose-normalized tacrolimus trough concentration after intravenous administration of metronidazole at 1000 mg/day for 8 days. When metronidazole was switched from intravenous to oral for 5 days, dose-normalized tacrolimus trough concentration was still increased by 52.4%. The magnitude of tacrolimus-metronidazole drug-drug interaction seems to be contingent upon the dose of metronidazole and the route of metronidazole administration. After cessation of metronidazole for one month, this drug-drug interaction, as assessed by weight-normalized tacrolimus dose, may still persist.

Conclusion

In the early period following renal transplantation, the long-term concomitant use of metronidazole is likely to elevate the trough concentration of tacrolimus. Gene screening for CYP3A5*3/*3 and ABCB1 3435C>T in recipients of solid organ transplants may support individualized tacrolimus prescribing and facilitate the mitigation of risks associated with drug-drug interactions.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002364104250701091104
2025-07-11
2026-02-01

  • From This Site

    /content/journals/cdm/10.2174/0113892002364104250701091104
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DidilescuA.C. VacaruR.P. PronkC. ScheauC. LazuA. DanL.P. BrandH.S. Oral diseases after liver transplantation: A systematic review and meta-analysis.Br. Dent. J.2021231211712410.1038/s41415‑021‑3219‑134302095
     [Google Scholar]
  2. SarmentoD.J.S. Aires AntunesR.S.C.C. CristelliM. Braz-SilvaP.H. MacielR. PestanaJ.O.M.A. GallottiniM. Oral manifestations of allograft recipients immediately before and after kidney transplantation.Acta Odontol. Scand.202078321722210.1080/00016357.2019.168568031718409
     [Google Scholar]
  3. Nunes-dos-SantosD.L. GomesS.V. RodriguesV.P. PereiraA.L.A. Periodontal status and clinical outcomes in kidney transplant recipients: A systematic review.Oral Dis.2020261223410.1111/odi.1304030661274
     [Google Scholar]
  4. DidilescuA.C. LazuA. PronkC. VacaruR.P. BrandH.S. Clinical periodontal and dental findings in liver transplant patients: A systematic review and meta-analysis.Br. Dent. J.2020228210811610.1038/s41415‑020‑1196‑431980788
     [Google Scholar]
  5. BarrachR.H. SouzaM.P. SilvaD.P. LopezP.S. MontovaniJ.C. Oral changes in individuals undergoing hematopoietic stem cell transplantation.Rev. Bras. Otorrinolaringol.201581214114710.1016/j.bjorl.2014.04.00425458262
     [Google Scholar]
  6. PrytułaA. CransbergK. RaesA. Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: Is it relevant in clinical practice?Pediatr. Nephrol.20193471201121010.1007/s00467‑018‑4030‑330058048
     [Google Scholar]
  7. YuM. LiuM. ZhangW. MingY. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation.Curr. Drug Metab.201819651352210.2174/138920021966618012915194829380698
     [Google Scholar]
  8. LauA.H. LamN.P. PiscitelliS.C. WilkesL. DanzigerL.H. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.Clin. Pharmacokinet.199223532836410.2165/00003088‑199223050‑000021478003
     [Google Scholar]
  9. LampK.C. FreemanC.D. KlutmanN.E. LacyM.K. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.Clin. Pharmacokinet.199936535337310.2165/00003088‑199936050‑0000410384859
     [Google Scholar]
  10. DingsdagS.A. HunterN. Metronidazole: An update on metabolism, structure–cytotoxicity and resistance mechanisms.J. Antimicrob. Chemother.201873226527910.1093/jac/dkx35129077920
     [Google Scholar]
  11. RoedlerR. NeuhauserM.M. PenzakS.R. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?Ann. Pharmacother.200741465365810.1345/aph.1H40117374625
     [Google Scholar]
  12. EarlyC.R. ParkJ.M. DorschM.P. PogueK.T. HaniganS.M. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for C lostridium difficile.Transpl. Infect. Dis.201618571472010.1111/tid.1258827501504
     [Google Scholar]
  13. Lee PageR.II KlemP.M. RogersC. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy.Ann. Pharmacother.20053961109111310.1345/aph.1E39915855244
     [Google Scholar]
  14. HerzigK. JohnsonD.W. Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy.Nephrol. Dial. Transplant.1999142521b52310.1093/ndt/14.2.521b10069238
     [Google Scholar]
  15. JouretF. SneyersB. GoffinE. Castanares-ZapateroD. Interaction between tacrolimus and clindamycin.NDT Plus201034422424[J].25949453
     [Google Scholar]
  16. HeJ. YuY. YinC. LiuH. ZouH. MaJ. YangW. LiuY. ZhongL. ChenX. Clinically significant drug‐drug interaction between tacrolimus and fluconazole in stable renal transplant recipient and literature review.J. Clin. Pharm. Ther.202045226426910.1111/jcpt.1307531756280
     [Google Scholar]
  17. MimuraA. YamaoriS. IkemuraN. KatsuyamaY. MatsuzawaN. OhmoriS. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once‐daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation.J. Clin. Pharm. Ther.2019444jcpt.1283410.1111/jcpt.1283430950099
     [Google Scholar]
  18. WangJ.S. BackmanJ.T. KivistöK.T. NeuvonenP.J. Effects of metronidazole on midazolam metabolism in vitro and in vivo.Eur. J. Clin. Pharmacol.200056855555910.1007/s00228000020111151744
     [Google Scholar]
  19. HaasC.E. KaufmanD.C. DiCenzoR.C. Effects of metronidazole on hepatic CYP3A4 activity.Pharmacotherapy200121101192119510.1592/phco.21.15.1192.3389611601665
     [Google Scholar]
  20. KimK.A. ParkJ.Y. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.Eur. J. Clin. Pharmacol.201066772172510.1007/s00228‑010‑0797‑220306185
     [Google Scholar]
  21. TanS.Y. KanE. LimW.Y. ChayG. LawJ.H.K. SooG.W. BukhariN.I. SegarraI. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.J. Pharm. Pharmacol.201163791892510.1111/j.2042‑7158.2011.01296.x21635257
     [Google Scholar]
  22. DilgerK. FuxR. RöckD. MörikeK. GleiterC.H. Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: A double drug interaction study.J. Clin. Pharmacol.200747121532153910.1177/009127000730861718048573
     [Google Scholar]
  23. AmonI. AmonK. HüllerH. Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages.Int. J. Clin. Pharmacol. Biopharm.1978168384386[J].357311
     [Google Scholar]
  24. ButtarH.S. SiddiquiW.H. MoffattJ.H. The disposition of [14C]metronidazole in rats following vaginal and oral administration.J. Pharm. Pharmacol.197931154254410.1111/j.2042‑7158.1979.tb13580.x39996
     [Google Scholar]
  25. SinghD.K. AhireD. DavydovD.R. PrasadB. Differential tissue abundance of membrane-bound drug metabolizing enzymes and transporter proteins by global proteomics.Drug Metab. Dispos.202452111152116010.1124/dmd.124.00147738641346
     [Google Scholar]
  26. PrasadB. GaedigkA. VranaM. GaedigkR. LeederJ.S. SalphatiL. ChuX. XiaoG. HopC.E.C.A. EversR. GanL. UnadkatJ.D. Ontogeny of hepatic drug transporters as quantified by LC‐MS/MS proteomics.Clin. Pharmacol. Ther.2016100436237010.1002/cpt.40927301780
     [Google Scholar]
  27. KounasS.P. LetsasK.P. SiderisA. EfraimidisM. KardarasF. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.Pacing Clin. Electrophysiol.200528547247310.1111/j.1540‑8159.2005.09348.x15869686
     [Google Scholar]
  28. PattersonB.D. Possible interaction between metronidazole and carbamazepine.Ann. Pharmacother.199428111303130410.1177/1060028094028011187849350
     [Google Scholar]
  29. CookeC.E. SklarG.E. NappiJ.M. Possible pharmacokinetic interaction with quinidine: Ciprofloxacin or metronidazole?Ann. Pharmacother.199630436436610.1177/1060028096030004088729890
     [Google Scholar]
  30. Zylber-KatzE. RubingerD. BerlatzkyY. Cyclosporine interactions with metronidazole and cimetidine.Drug Intell. Clin. Pharm.198822650450510.1177/1060028088022006163293960
     [Google Scholar]
  31. GnanapandithanK. KarthikN. GerberJ. Methadone, Metoclopramide and Metronidazole Interaction Causing Torsades de Pointes.Clin. Pract.202111110110510.3390/clinpract1101001533562182
     [Google Scholar]
  32. GulbisA.M. CulottaK.S. JonesR.B. AnderssonB.S. Busulfan and metronidazole: An often forgotten but significant drug interaction.Ann. Pharmacother.2011457-8102410.1345/aph.1Q08721730282
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002364104250701091104
Loading
Unexpected Clinically Significant Drug-Drug Interaction between Tacrolimus and Metronidazole in the Early Period after Renal Transplantation: A Literature Review
Current Drug Metabolism 26, 153 (2025); https://doi.org/10.2174/0113892002364104250701091104
/content/journals/cdm/10.2174/0113892002364104250701091104
/content/journals/cdm/10.2174/0113892002364104250701091104
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): CYP3A; drug-drug interaction; gene screening; metronidazole; renal transplantation; Tacrolimus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test